[1] |
ZHAO Mudan, ZHU Minghui, ZHANG Huan, ZHAO Yuanyang, QIN Jing.
Pharmaceutical Care of a Case of Diabetic Foot Infection Caused by Proteus penneri
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 937-940.
|
[2] |
ZHANG Caixia, ZHOU Yi, TAN Lu, CHEN Wenming, LIU Yang, YOU Yu.
Pharmaceutical care of pulmonary aspergillus infection secondary to sepsis
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1064-1067.
|
[3] |
YAN Yan, LIU Naiyi, QIAO Ling, ZHANG Yi, YANG Chen.
One case of fulminant type 1 diabetes mellitus induced by allopurinol tablets hypersensitivity syndrome
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(9): 1068-1070.
|
[4] |
LIN Yanxin, LIU Yanhui, DONG Jing, YAO Jiachen, LI Wenyan.
Pharmaceutical care of acute liver injury in a patient with colon cancer induced by irinotecan
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(6): 693-696.
|
[5] |
LI haiyan, YANG Zhongxu, LIU Yuekun, WANG Lihong.
Pharmaceutical care of serious adverse reactions due to methotrexate treatment of ectopic pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 454-456.
|
[6] |
JI Qiuxia, JIN Jian, ZHANG Bin.
Pharmaceutical care for immune-related adverse events induced by toripalimab
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(3): 346-348.
|
[7] |
SHEN Jianghua, KONG Chao, PAN Fumin, CHU Yanqi.
Pharmaceutical care of a case with vertebral osteomyelitis of Coxiella burnetiid
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(10): 1166-1168.
|
[8] |
SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian.
Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
|
[9] |
ZHANG Xialan, YUAN Jing, WU Bin, QIN Yuanyuan.
Medications of apatinib mesylate in patients with malignant tumors
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 927-932.
|
[10] |
WANG Ran, LI Yifan, LIU Xiaoyan, FENG Xin.
One case of pharmaceutical care of drug exposure during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 933-934.
|
[11] |
LIU Jing, XIA Liang, ZHANG Shijie.
Pharmaceutical care of a patient with acute pancreatitis complicated with multiple drug allergy undergoing drug stimulation test
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 822-824.
|
[12] |
WANG Ran, FENG Xin, DU Boran.
Advances in risk assessment and pharmaceutical care of pregnancy medication exposure during perinatal period
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 836-840.
|
[13] |
HUO Peiqiong, ZHENG Peng, SU Zhenhao.
Pharmacovigilance in retail pharmacies for special or major diseases
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 428-432.
|
[14] |
ZHENG Yujing, ZHAO Zinan, JIN Pengfei, ZHAO Fei, HU Xin, ZHANG Yatong.
Active monitoring of adverse reactions of capecitabine-induced hand-foot syndrome based on the hospital information system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 441-443.
|
[15] |
YANG Yan, ZHOU Dexi, WU Xinli, XUE Shuya, DING Haihua, ZHANG Quan, ZHANG Yunling.
Eighty-four cases of adverse drug reactions caused by novel anti-tumor drugs
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(3): 334-338.
|